Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acetaminophen + aspirin + caffeine is an oral fixed-dose combination analgesic used to treat mild to moderate pain such as tension headaches and migraine. It contains three active ingredients: - Acetaminophen (paracetamol), an analgesic and antipyretic that reduces pain and fever by acting on the central nervous system. - Aspirin (acetylsalicylic acid), a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce inflammation and pain. - Caffeine is a central nervous system stimulant that acts as an adenosine receptor antagonist; it enhances the analgesic effects of acetaminophen and aspirin while also helping relieve headache symptoms. This triple combination has been shown to be more effective than any of its individual components or dual combinations for acute headache relief. The product is available over-the-counter in many countries under various brand names. Chronic or excessive use can increase risks of hepatotoxicity (from acetaminophen), gastrointestinal bleeding (from aspirin), renal papillary necrosis with long-term high doses of both acetaminophen and aspirin together; caffeine may cause insomnia or palpitations in sensitive individuals[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + aspirin + caffeine.